Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
claudin-9 CRISPR Activation Plasmid (h): sc-403166-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- claudin-9 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- claudin-9 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by claudin-9 CRISPR Activation Plasmid (h) and claudin-9 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the CLDN9 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: claudin-9 Antibody (E-7): sc-398836
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
claudin-9 CRISPR Activation Plasmid (h) | sc-403166-ACT | 20 µg | $397.00 | |||
claudin-9 CRISPR Activation Plasmid (h2) | sc-403166-ACT-2 | 20 µg | $397.00 |
CLDN9 encodes claudin-9, a tetraspanning tight junction protein that helps establish epithelial barrier integrity and selective paracellular permeability. As part of claudin-based junctional strands, claudin-9 coordinates cell–cell adhesion and apical–basal polarity and interfaces with junctional scaffolds that couple tight junctions to actin remodeling and epithelial differentiation programs. Altered claudin expression patterns are frequently associated with disrupted barrier function, changes in tissue organization, and epithelial-to-mesenchymal phenotypes that influence invasion and metastasis-related behaviors. CLDN9 is therefore relevant for studying tight junction assembly, epithelial morphogenesis, and disease-linked barrier dysregulation in human cell models.
claudin-9 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CLDN9 expression without altering the underlying DNA sequence.
claudin-9 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CLDN9 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CLDN9 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous claudin-9 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CLDN9 locus and enabling the study of claudin-9-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of claudin-9 pathway restoration in tumor cells with silenced or reduced CLDN9 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.